Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

Mary Lou Clements-Mann, Mamodikoe K. Makhene, Jacek Mrukowicz, Peter F. Wright, Yasutaka Hoshino, Karen Midthun, Ellen Sperber, Ruth A Karron, Albert Z. Kapikian

Research output: Contribution to journalArticle

Abstract

Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

Original languageEnglish (US)
Pages (from-to)2715-2725
Number of pages11
JournalVaccine
Volume17
Issue number20-21
DOIs
StatePublished - Jun 4 1999

Fingerprint

adult children
Rotavirus Vaccines
Rotavirus
serotypes
immune response
vaccines
Safety
cattle
Reassortant Viruses
Immunoglobulin A
sheds
dosage
Vaccines
neutralization
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
mouth
pathogenicity
Serogroup
Antibodies

Keywords

  • Diarrheal vaccines
  • Human-bovine reassortant rotavirus vaccines
  • Live attenuated virus vaccines
  • Pediatric vaccines
  • Rotavirus vaccines

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. / Clements-Mann, Mary Lou; Makhene, Mamodikoe K.; Mrukowicz, Jacek; Wright, Peter F.; Hoshino, Yasutaka; Midthun, Karen; Sperber, Ellen; Karron, Ruth A; Kapikian, Albert Z.

In: Vaccine, Vol. 17, No. 20-21, 04.06.1999, p. 2715-2725.

Research output: Contribution to journalArticle

Clements-Mann, Mary Lou ; Makhene, Mamodikoe K. ; Mrukowicz, Jacek ; Wright, Peter F. ; Hoshino, Yasutaka ; Midthun, Karen ; Sperber, Ellen ; Karron, Ruth A ; Kapikian, Albert Z. / Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. In: Vaccine. 1999 ; Vol. 17, No. 20-21. pp. 2715-2725.
@article{8ac9e2f12b624eae96faa67724502deb,
title = "Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants",
abstract = "Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50{\%}) by D x UK; 9/11 (82{\%}) by DS-1 x UK; 8/10 (80{\%}) by P x UK and 13/14 (93{\%}) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.",
keywords = "Diarrheal vaccines, Human-bovine reassortant rotavirus vaccines, Live attenuated virus vaccines, Pediatric vaccines, Rotavirus vaccines",
author = "Clements-Mann, {Mary Lou} and Makhene, {Mamodikoe K.} and Jacek Mrukowicz and Wright, {Peter F.} and Yasutaka Hoshino and Karen Midthun and Ellen Sperber and Karron, {Ruth A} and Kapikian, {Albert Z.}",
year = "1999",
month = "6",
day = "4",
doi = "10.1016/S0264-410X(98)00497-6",
language = "English (US)",
volume = "17",
pages = "2715--2725",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "20-21",

}

TY - JOUR

T1 - Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

AU - Clements-Mann, Mary Lou

AU - Makhene, Mamodikoe K.

AU - Mrukowicz, Jacek

AU - Wright, Peter F.

AU - Hoshino, Yasutaka

AU - Midthun, Karen

AU - Sperber, Ellen

AU - Karron, Ruth A

AU - Kapikian, Albert Z.

PY - 1999/6/4

Y1 - 1999/6/4

N2 - Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

AB - Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

KW - Diarrheal vaccines

KW - Human-bovine reassortant rotavirus vaccines

KW - Live attenuated virus vaccines

KW - Pediatric vaccines

KW - Rotavirus vaccines

UR - http://www.scopus.com/inward/record.url?scp=0033522950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033522950&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(98)00497-6

DO - 10.1016/S0264-410X(98)00497-6

M3 - Article

VL - 17

SP - 2715

EP - 2725

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 20-21

ER -